未找到相关数据
Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
被引：3
作者：
Xu, Jian-Ming
Liu, Rongrui
Ba, Yi
Jiang, Da
Wang, Mingxia
Zheng, Yulong
Wei, Jia
Bai, Yu-Xian
Lin, Lizhu
Xiong, Jianping
Zhu, Xixi
Zhao, Chuanhua
Jia, Ru
Zhang, Yun
Liu, Jianzhi
Zhang, Gairong
Li, Guangze
Wang, Quanren
机构：
[1] PLA, Gen Hosp, Dept GI Oncol, Med Ctr 5, Beijing, Peoples R China
[2] Tianjin Med Univ, Canc Inst & Hosp, Dept Digest Oncol, Tianjin, Peoples R China
[3] Hebei Med Univ, Hosp 4, Dept Med Oncol, Shijiazhuang, Hebei, Peoples R China
[4] Hebei Med Univ, Hosp 4, Shijiahuang, Peoples R China
[5] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[6] Nanjing Univ, Sch Med, Affiliated Hosp, Nanjing Dram Tower Hosp, Nanjing, Jiangsu, Peoples R China
[7] Harbin Med Univ, Canc Hosp, Harbin, Heilongjiang, Peoples R China
[8] Guangzhou Univ Tradit Chinese Med, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China
[9] Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China
[10] Jiangsu HengRui Med Co Ltd, Shanghai, Peoples R China
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.4060
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4060
引用
收藏
页数：2
相关论文